Keypoints:
• The significance of recurrence scores in dictating adjuvant chemotherapy
• The ongoing OFSET trial and its potential impact on treatment decisions
• Insights into the use of genomic assays like MammaPrint and RS-Clin
• The evolving landscape of treatment options for locally advanced and metastatic breast cancer
• The latest on PARP inhibitors, T-DXd, and other novel therapies
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain had the pleasure of welcoming Dr. Kevin Kalinsky, a breast medical oncologist and director of the breast cancer program at the Winship Cancer Institute of Emory University. We continued our breast cancer series by diving into hormone receptor-positive breast cancer, a rapidly evolving area in oncology.
Dr. Kalinsky shared insights on the use of OncotypeDX to guide treatment decisions for premenopausal and postmenopausal women, emphasizing the importance of menopausal status and the recurrence score in determining the need for chemotherapy. He discussed the ongoing OFSET trial, which aims to clarify the role of ovarian function suppression in early-stage patients.
We also explored the utility of genomic assays like MammaPrint and RS-Clin, and how they can complement OncotypeDX in treatment planning. Dr. Kalinsky highlighted the significance of anthracyclines in locally advanced disease, particularly for patients with high recurrence scores and multiple lymph nodes involved.
As we transitioned to adjuvant settings, we discussed the recent approvals of CDK4-6 inhibitors, including Abemaciclib and Ribociclib, and the role of PARP inhibitors like Olaparib for BRCA-positive patients. Dr. Kalinsky provided valuable clinical pearls on sequencing these therapies and managing side effects.
In the metastatic setting, we examined the latest treatment options, including the novel PI3K inhibitor, Inavolisib, and the exciting developments surrounding antibody-drug conjugates (ADCs) like T-DXd and Dato-DXd. Dr. Kalinsky shared his approach to sequencing these therapies, emphasizing the importance of patient-specific factors and the need for careful monitoring of side effects.
Overall, this episode was packed with valuable information on the current landscape of hormone receptor-positive breast cancer treatment, and we hope our listeners find it as enlightening as we did. Thank you for joining us, and be sure to check out our other discussions on oncology topics!
Listen Podcast on Your Favourite Platform
